European Patent Office

T 1708/18 (PCSK9 variants/BRISTOL-MYERS SQUIBB) vom 14.02.2022

Europäischer Rechtsprechungsidentifikator
ECLI:EP:BA:2022:T170818.20220214
Datum der Entscheidung
14. Februar 2022
Aktenzeichen
T 1708/18
Antrag auf Überprüfung von
-
Anmeldenummer
07873840.8
Verfahrenssprache
Englisch
Verteilung
Nicht verteilt (D)
Amtsblattfassungen
Keine AB-Links gefunden
Weitere Entscheidungen für diese Akte
-
Zusammenfassungen für diese Entscheidung
Zusammenfassung von EPC2000 Art 117
Bezeichnung der Anmeldung
Polynucleotides encoding novel PCSK9 variants
Name des Antragstellers
Bristol-Myers Squibb Company
Name des Einsprechenden
Regeneron Pharmaceuticals, Inc.
Sanofi
Pfizer Inc.
Kammer
3.3.04
Leitsatz
-
Relevante Rechtsnormen
European Patent Convention Art 54
Schlagwörter
Novelty - (no)
Orientierungssatz
1. The issue of which standard of disclosure applies when assessing the legal question of novelty and the issue of which standard of proof applies when assessing evidence and factual questions are distinct and unrelated. The fact that the standard of disclosure required for a finding of lack of novelty (or for allowing an amendment to the application under Article 123(2) EPC) is the standard of a direct and unambiguous disclosure is immaterial for the question of what standard of proof applies when considering evidence and factual issues in the context of novelty (or inventive step) (see point 16).
2. The standard of proof generally applied at the EPO for deciding on an issue of fact is the balance of probabilities. According to this standard, the EPO must base its decisions on statements of fact which, based on the available evidence, are more likely than not to be true. This standard also applies when examining factual issues in the context of novelty (see point 14).
Zitierende Akten
T 0358/22

Order

For these reasons it is decided that:

1. The decision under appeal is set aside.

2. The patent is revoked.